1997 FDA SCIENTIFIC ACHIEVEMENT AWARDS
The Center and Office of Regulatory Affairs (ORA) Scientific Achievement Awardees have been selected by the respective
Center/ORA selection committees in the categories of "Excellence in Analytical Science," "Excellence in Laboratory Science,"
and "Excellence in Review Science."
The Center/ORA award recipients are:
- Excellence in Analytical Science
- Robert A. Boykins - CBER
- For exceptional performance in the development of analytical methodology critical to the regulation of biologics.
- C. David Lytle, Ph.D. - CDRH
- For the development of innovative, sensitive methods to evaluate the effectiveness of barrier materials in preventing in preventing the passage of infectious agents.
- Mary L. Tortorello, Ph.D. - CFSAN
- For superior performance in the interest of public health in developing and applying a rapid assay for the detection of Escherichia coli 0157:H7 in foods..
- Beta-lactam Method Development Team - Pak-Sin Chu, Ph.D., Maureen A. Ngoh, Ph.D., Patricia G. Schermerhorn, M.S., and Jurgen von Bredow, Ph.D. - CVM
- For the development of regulatory methods of analysis for beta-lactam drug residues in milk by liquid chromatography.
- Jackson O. Lay, Jr., Ph.D. - NCTR
- For leadership in the development of a new method for the identification of bacterial: matrix-assisted laser desorption ionization mass spectrometry.
- Susan Ting - ORA
For exceptional contribution to consumer protection through outstanding drug inspectional and analytical
expertise in the agency's high priority NDA and ANDA drug pre-approval program.
- Excellence in Laboratory Science
- Hana Golding, Ph.D. - CBER
- For outstanding studies in the field of HIV-1 pathogenesis, viral cell-entry, and the evaluation of agents designed to
block viral entry.
- Hao Zhang, M.D. - CDER
- For developing the palindromic oligonucleotide-directed enzymatic reaction method for measuring deoxyribonucleotide
5'-triphosphates in cells and tissues to improve the evaluation of new antiviral drugs.
- Toxoplasma IgM Commercial Kits Pilot Evaluation Work Team - Charles R. Clavet, M.S. (ORA), Carol L. Herman (CDRH),
Elizabeth A. Keville (ORA), Roxanne G. Shively, M.S. (CDRH), Tom Simms (CDRH), George William Varney (ORA), - CDRH
- For exceptional planning and performance of a study of Toxoplasma IgM commercial kits, thereby protecting public
health through physician notification of kit performance and inaccuracies.
- Robert L. Bronaugh, Ph.D. - CFSAN
- For excellence in the development and application of skin penetration methodologies to the safety evaluation of
cosmetic ingredients.
- Michael J. Myers, Ph.D. - CVM
- For research investigating the interaction of immune function and drug metabolism in domestic animals.
- Syed Ali, Ph.D. - NCTR
- For the scientific advancement in an area of neuroscience/neurotoxicology of critical importance to FDA's mission that
represents a unique resource to NCTR/FDA and the neuroscience community at large.
- Nicholas Falcone, M.S. - ORA
- For scientific expertise in NDA/ANDA coordination, research and inspectional activities.
- Excellence in Review Science
- Mei-ying W. Yu, Ph.D. - CBER
- For outstanding contribution to the public health by ensuring the viral safety of immune globulin products.
- Office of Pharmaceutical Sciences Microbiologists - Peter H. Cooney, Ph.D., Vivian Greenman, David Hussong, Ph.D.,
Carol Keller Vincent, M.S., Paul S. Stinavage, Ph.D., Patricia F. Hughes, Ph.D., Brenda Uratani, Ph.D., Neal J. Sweeney, Ph.D.,
Andrea S. High, Ph.D., James L. McVey, M.S., Kenneth H. Muhvich, Ph.D. - CDER
- For exceptional contributions to review science as exemplified in the review of microbiological quality of drug products
and the development of regulatory positions.
- David M. Whipple - CDRH
- For scientific review excellence and regulatory leadership in the development and harmonization of FDA special controls
with national and international standards for contact lens products.
- Daniel A. Benz, Ph.D. - CVM
- For innovative application of nutritional and physiological expertise to the scientific review process for new animal drugs
in free-choice feed supplements.
Each of these Center/ORA awardees are now being considered for the FDA Scientific Achievement Awards.
Recipients of the FDA-level Scientific Achievement Awards will receive a $3000 cash award, and a personal letter and certificate
from the Commissioner.
The 1997 FDA Scientific Achievement Award recipients will be announced at the December 9 ceremony, to be held at the
Natcher Conference Center, at 10:45 a.m.
Information from http://first.fda.gov